Mind Medicine Australia

Mind Medicine Australia is Australia's leading not-for-profit organisation working towards the use of medicinal psilocybin and MDMA-assisted therapies to treat a range of mental illnesses. Mind Medicine Australia exists to help alleviate the suffering caused by our accelerating mental illness epidemic, through expanding the treatment options available to medical practitioners and their patients. Psychedelic-assisted therapies offer enormous potential in providing a meaningful alternative to current treatments for mental illness. PTSD is a debilitating condition that affects tens of millions of people worldwide, with many more trauma victims diagnosed with comorbid conditions such as depression, anxiety and eating disorders. In recent clinical trials, MDMA has been shown to produce outstanding remission rates, restoring patient safety and self-agency even for individuals who have suffered with PTSD for many years, and for whom many treatments have failed. Results from Phase 2 clinical trials over the past decade have been so compelling that the Food and Drug Administration (FDA) in the United States recently designated MDMA-assisted psychotherapy as a 'Breakthrough Therapy'. This designation highlights the FDA's anticipation that these therapies may offer substantial advantage over current treatments. If forthcoming Phase 3 results confirm these treatments are effective, MDMA-assisted treatment of PTSD may become a prescription medicine as early as 2022 in some jurisdictions. The wave of clinical psychedelic research and regulatory support is rapidly building, with psychedelic-assisted treatments also becoming available through Special Access Schemes around the world.